All In Biotech

Drug Trial Radar · NCT07291635

Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine

A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 728 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

728

Planned (sponsor's estimate)

Start

Feb 25, 2026

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Aramis Biotechnologies Inc.Industry
Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.

Conditions

  • Influenza

Interventions

  • Recombinant Influenza vaccine candidateBiological

    Plant-Based Seasonal Recombinant Trivalent TVLP Influenza Vaccine

  • Commercial Influenza vaccineBiological

    Influenza vaccine commercially available on the Canadian market

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immediate AEsTime frame: 30 minutes
  2. Solicited local and systemic AEsTime frame: 7 days
  3. Unsolicited AEsTime frame: 28 days
  4. Urine, haematological and blood biochemistry valuesTime frame: Screening and Day 3
  5. Deaths, SAEs, AEs leading to withdrawal, TEAEsTime frame: 182 days
  6. HI antibody response (GMT)Time frame: Day 0 and Day 28

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Canadian Center for Vaccinology (CCfV) - IWK Health

    Halifax, Nova Scotia, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Vaccine Study Centre of McGill University Health Centre

    Pierrefonds, Quebec, Canada

  • CHU de Québec - Université Laval

    Québec, Quebec, Canada

  • Diex Recherche - Sherbrooke

    Sherbrooke, Quebec, Canada

  • Diex Recherche - Trois-Rivières

    Trois-Rivières, Quebec, Canada

  • Diex Recherche - Victoriaville

    Victoriaville, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.